Your browser doesn't support javascript.
loading
Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab.
Hutchins, Beth; Starling, Gary C; McCoy, Mark A; Herzyk, Danuta; Poulet, Frederique M; Dulos, John; Liu, Liming; Kang, Soonmo Peter; Fayadat-Dilman, Laurence; Hsieh, Mark; Andrews, Christine L; Ayanoglu, Gulesi; Cullen, Constance; Malefyt, Rene de Waal; Kastelein, Robert A; Saux, Sabine Le; Lee, Julie; Li, Sophie; Malashock, Dan; Sadekova, Svetlana; Soder, George; van Eenennaam, Hans; Willingham, Aarron; Yu, Ying; Streuli, Michel; Carven, Gregory J; van Elsas, Andrea.
Affiliation
  • Hutchins B; Merck & Co., Inc., Kenilworth, New Jersey. beth.hutchins@merck.com.
  • Starling GC; Merck & Co., Inc., Kenilworth, New Jersey.
  • McCoy MA; Merck & Co., Inc., Kenilworth, New Jersey.
  • Herzyk D; Merck & Co., Inc., Kenilworth, New Jersey.
  • Poulet FM; Merck & Co., Inc., Kenilworth, New Jersey.
  • Dulos J; Merck & Co., Inc., Kenilworth, New Jersey.
  • Liu L; Galapagos, Leiden, The Netherlands.
  • Kang SP; Merck & Co., Inc., Kenilworth, New Jersey.
  • Fayadat-Dilman L; Merck & Co., Inc., Kenilworth, New Jersey.
  • Hsieh M; Merck & Co., Inc., Kenilworth, New Jersey.
  • Andrews CL; Merck & Co., Inc., Kenilworth, New Jersey.
  • Ayanoglu G; Merck & Co., Inc., Kenilworth, New Jersey.
  • Cullen C; Merck & Co., Inc., Kenilworth, New Jersey.
  • Malefyt RW; Merck & Co., Inc., Kenilworth, New Jersey.
  • Kastelein RA; Apollo Biologics Consulting, Los Angeles, California.
  • Saux SL; Merck & Co., Inc., Kenilworth, New Jersey.
  • Lee J; Synthekine, Inc., Menlo Park, California.
  • Li S; Merck & Co., Inc., Kenilworth, New Jersey.
  • Malashock D; Synthekine, Inc., Menlo Park, California.
  • Sadekova S; Merck & Co., Inc., Kenilworth, New Jersey.
  • Soder G; Merck & Co., Inc., Kenilworth, New Jersey.
  • van Eenennaam H; Merck & Co., Inc., Kenilworth, New Jersey.
  • Willingham A; Merck & Co., Inc., Kenilworth, New Jersey.
  • Yu Y; Merck & Co., Inc., Kenilworth, New Jersey.
  • Streuli M; Merck & Co., Inc., Kenilworth, New Jersey.
  • Carven GJ; Merck & Co., Inc., Kenilworth, New Jersey.
  • van Elsas A; AIMM Therapeutics B.V., Amsterdam, The Netherlands.
Mol Cancer Ther ; 19(6): 1298-1307, 2020 06.
Article in En | MEDLINE | ID: mdl-32229606
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukocytes, Mononuclear / T-Lymphocytes / Antibodies, Monoclonal, Humanized / Programmed Cell Death 1 Receptor / Neoplasms Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukocytes, Mononuclear / T-Lymphocytes / Antibodies, Monoclonal, Humanized / Programmed Cell Death 1 Receptor / Neoplasms Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2020 Type: Article